The U.S. Justice Department says a subsidiary of Bristol, Tenn.-based King Pharmaceuticals Inc. has agreed to pay $42.5 million to settle allegations over the marketing of a painkiller. Prosecutors announced the settlement yesterday with Alpharma Inc., which was bought by King in 2008, in a whistleblower lawsuit. The Suit claimed Alpharma paid health care providers to induce them to promote or prescribe the morphine-based painkiller Kadian and made misrepresentations about the safety and efficacy of the drug. The settlement will be split between the federal government and various states and was a collaboration between the Justice Department and the U.S. attorney’s office in Maryland. A message left for a spokesman for King was not immediately returned Tuesday afternoon.